证券代码：300534 证券简称：陇神戎发 公告编号：2025-046 关于召开2025年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司 甘肃陇神戎发药业股份有限公司（以下简称"公司"）于2025年5月29日召开 第五届董事会第十九次会议，审议通过了《关于召开2025年第三次临时股东会的 议案》，同意于2025年6月17日召开公司2025年第三次临时股东会。现将具体事项 公告如下： 一、召开会议的基本情况 1.股东会届次：2025年第三次临时股东会。 2.股东会的召集人：公司董事会。 3.会议召开的合法、合规性：经公司第五届董事会第十九次会议审议，同意 召开公司2025年第三次临时股东会。本次股东会的召集程序符合有关法律、行政 法规、部门规章、规范性文件和《公司章程》的规定。 4.会议召开的日期、时间： （1）现场会议召开时间：2025年6月17日下午14:00 （2）网络投票时间：2025年6月17日 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年6月 17日9:15—9:25，9: ...

证券代码：300534 证券简称：陇神戎发 公告编号：2025-044 甘肃陇神戎发药业股份有限公司 第五届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 会议审议并通过了如下议案： 1.审议通过《关于修订〈公司章程〉的议案》 根据《中华人民共和国公司法》、中国证监会《上市公司章程指引》的相关 规定，结合公司实际情况，公司对《公司章程》中相关条款进行了修订。 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）披露的《关于 修订<公司章程>的公告》以及修订后的《公司章程》。 表决结果：同意 4 票，反对 0 票，弃权 0 票。 一、监事会会议召开情况 甘肃陇神戎发药业股份有限公司（以下简称"公司"）第五届监事会第十一 次会议通知于 2025 年 5 月 26 日以电子邮件方式等方式发出，会议于 2025 年 5 月 29 日在公司六楼会议室现场召开。本次会议由公司监事会主席邓育阳先生主 持，应出席会议监事 4 人，实际出席会议监事 4 人。本次会议的召集、召开符合 《公司法》等有关法律、行政法规、部门规章和《公司章 ...

证券代码：300534 证券简称：陇神戎发 公告编号：2025-043 甘肃陇神戎发药业股份有限公司 第五届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 甘肃陇神戎发药业股份有限公司（以下简称"公司"）第五届董事会第十九 次会议通知于 2025 年 5 月 26 日以电子邮件方式等方式发出，会议于 2025 年 5 月 29 日在公司六楼会议室现场召开。本次会议由公司董事长康永红先生主持， 应出席会议董事 9 人，实际出席会议董事 9 人，公司监事、高级管理人员列席了 会议。本次会议的召集、召开符合《公司法》等有关法律、行政法规、部门规章 和《公司章程》的相关规定，合法有效。 二、董事会会议审议情况 会议审议并通过了如下议案： 1.审议通过《关于修订〈公司章程〉的议案》 根据《中华人民共和国公司法》、中国证监会《上市公司章程指引》的相关 规定，结合公司实际情况，公司对《公司章程》中相关条款进行了修订。公司董 事会提请股东会授权董事会及其授权的相关人员具体办理本次《公司章程》修订 所涉及的工商变更登记、备案等 ...

Market Overview - The Shanghai Composite Index fell by 0.18% on May 27, with 13 industries experiencing gains, led by textiles and apparel (up 1.30%) and the pharmaceutical and biotechnology sector (up 0.97) [1] - The net outflow of capital from the two markets was 19.519 billion yuan, with 8 industries seeing net inflows, primarily in the food and beverage sector, which had a net inflow of 1.006 billion yuan [1] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector rose by 0.97%, with a net inflow of 650 million yuan, and out of 476 stocks in this sector, 372 stocks increased in value, while 94 stocks declined [2] - The top three stocks with the highest net inflow were Longshen Rongfa (1.33 billion yuan), Yuheng Pharmaceutical (1.27 billion yuan), and WuXi AppTec (1.21 billion yuan) [2] - The sector also had notable outflows, with the top three stocks experiencing the largest net outflows being Yixin Pharmacy (-845.979 million yuan), Huadong Medicine (-829.898 million yuan), and Heng Rui Medicine (-752.640 million yuan) [4] Capital Flow in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included Longshen Rongfa (up 11.29%), Yuheng Pharmaceutical (up 9.89%), and WuXi AppTec (up 0.86%) [2] - Conversely, the stocks with the largest capital outflows included Yixin Pharmacy (down 5.20%), Huadong Medicine (up 0.38%), and Heng Rui Medicine (up 0.13%) [4]

Group 1: Market Overview - The People's Bank of China conducted a 7-day reverse repo operation of 448 billion yuan at an interest rate of 1.40% on May 27, with 357 billion yuan of reverse repos maturing on the same day [1][5] - A-shares opened slightly lower but showed signs of recovery, with the Shanghai Composite Index fluctuating and turning positive [5][6] - The consumer sector, particularly food and beverage, showed initial strength, while the pharmaceutical sector rebounded [6][12] Group 2: Pharmaceutical Sector - The pharmaceutical and biotechnology sector experienced a partial rebound, with notable stocks such as Longshen Rongfa hitting the daily limit, and Sanofi Guojian rising over 10% [12][13] - Hong Kong pharmaceutical stocks also saw gains, with notable increases in companies like CSPC Pharmaceutical and China Biologic Products [8][14] Group 3: Nuclear Power Sector - The nuclear power sector continued its recent strong performance, with stocks like Shangwei Co. and Rongfa Nuclear Power achieving multiple consecutive gains [9][11] - Recent reports indicate a positive outlook for the controllable nuclear fusion industry, driven by favorable policies and increased financing [11] Group 4: Food and Beverage Sector - The food and beverage sector saw a surge, with stocks like Kuaijishan and Junyao Health achieving significant gains [15][16] - Kuaijishan's market capitalization surpassed that of Guyue Longshan, establishing it as a leading player in the yellow wine industry [15] Group 5: Cultivated Diamond Sector - The cultivated diamond sector experienced a sharp rise, with stocks like Huanghe Xuanfeng and Huifeng Diamond hitting the daily limit [17][18] - Huanghe Xuanfeng announced a partnership to establish a joint venture focused on advanced semiconductor materials, which is expected to enhance the development of high-performance thermal materials [19]

证券代码：300534 证券简称：陇神戎发 公告编号：2025-042 甘肃陇神戎发药业股份有限公司 2024 年度分红派息实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股东大会审议通过利润分配方案的情况 1.甘肃陇神戎发药业股份有限公司（以下简称"公司"）于 2025 年 4 月 22 日召开的 2024 年年度股东大会审议通过了《2024 年度利润分配预案》，公司 2024 年度利润分配方案为：以截至 2024 年 12 月 31 日的公司总股本 303,345,000 股 为基数，向全体股东每 10 股派发现金红利人民币 0.20 元（含税），合计派发现 金红利人民币 6,066,900.00 元，不送红股，不以资本公积转增股本，剩余未分 配利润结转以后年度分配。分配预案经董事会审议后至实施权益分派的股权登记 日前，公司股本如发生变动，将按照分配总额不变的原则，对分配比例进行调整。 2.自分配方案披露至实施期间公司股本总额未发生变化。 3.本次实施的分配方案与 2024 年年度股东大会审议通过的分配方案一致。 4.本次分配方案的实施距离股 ...

证券代码：300534 证券简称：陇神戎发 公告编号：2025-041 甘肃陇神戎发药业股份有限公司 关于控股子公司完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司控股子公司甘肃药业集团三元医药有限公 司（以下简称"三元医药"）因经营工作需要，于近日完成了经营范围的工商变 更登记手续以及章程修订的备案工作，取得了兰州市城关区市场监督管理局核准 换发的《营业执照》。 一、新取得的《营业执照》所载具体信息 5.法定代表人：宋月红 6.注册资本：壹仟万元整 7.成立日期：2018 年 7 月 18 日 8.经营范围：许可项目：药品批发；药品进出口；第三类医疗器械经营；药 品零售；消毒器械销售；中药饮片代煎服务；食品销售（依法须经批准的项目， 经相关部门批准后方可开展经营活动） 一般项目：第一类医疗器械销售；第二类医疗器械销售；保健食品（预包装） 销售；医护人员防护用品零售；医用口罩零售；消毒剂销售（不含危险化学品）； 卫生用品和一次性使用医疗用品销售；化妆品零售；个人卫生用品销售；地产中 草药（不含中 ...

Core Viewpoint - The company achieved significant growth in Q1 2025, with revenue of 289 million yuan, a year-on-year increase of 13.52%, and a net profit attributable to shareholders of 24.21 million yuan, up 9.18%, marking the end of three consecutive quarters of decline [1] Financial Performance - The company reported a net profit of 26.92 million yuan after deducting non-recurring items, reflecting a year-on-year growth of 26.88% [1] - The revenue from the company's main products, including Yuanhu Zhitong Diban and Xuanfei Zhiso Heji, contributed to the stable growth in Q1 [1] Product Development and Market Strategy - The company focuses on its core business and actively develops OTC and untapped markets, which has laid a solid foundation for revenue growth [1] - The core product, Xuanfei Zhiso Heji, has shown strong sales growth, with revenue reaching 840 million yuan in 2024, a 29.76% increase from the previous year [2] - The company is upgrading its production capacity for Xuanfei Zhiso Heji, with a new production line set to be operational in May 2024, enhancing market supply capabilities [2] Innovation and R&D - The company has acquired 70% of the shares in an innovation research institute, which will accelerate the transformation of research results and improve product quality and competitiveness [3] - The company is also developing new products, including a blood dialysis concentrate and a plant-based beverage, while continuing to enhance its main products [3] Future Outlook - The company aims to maintain its focus on core operations and market expansion, with plans to implement various annual work tasks to improve operational efficiency [4]

Financial Performance - The company's revenue for Q1 2025 was CNY 289,443,116.82, representing a 13.52% increase compared to CNY 254,914,282.74 in the same period last year[5]. - Net profit attributable to shareholders was CNY 24,210,004.50, up 9.18% from CNY 22,141,028.38 year-on-year[5]. - The net profit after deducting non-recurring gains and losses increased by 26.88% to CNY 26,922,986.49 from CNY 21,218,616.75 in the previous year[5]. - Total operating revenue for the current period reached ¥289,443,116.82, an increase of 13.5% compared to ¥254,961,825.33 in the previous period[23]. - Net profit for the current period was ¥32,876,395.14, representing a growth of 6.6% from ¥30,849,905.40 in the previous period[24]. - The company's gross profit margin improved to approximately 16.5%, compared to 14.5% in the previous period[23]. - Basic earnings per share rose to ¥0.0798 from ¥0.0731, an increase of 9.2%[25]. Cash Flow and Operating Activities - The net cash flow from operating activities decreased by 124.47% to -CNY 32,384,718.82, compared to CNY 84,710,636.25 in the same period last year[5]. - Operating cash inflow totaled $326,936,319.75, down from $342,028,825.91 in the previous period, representing a decrease of approximately 4.1%[27]. - Operating cash outflow increased significantly to $359,321,038.57 from $209,706,087.53, marking an increase of about 71.4%[28]. - Cash received from sales of goods and services was $312,167,100.41, down from $325,603,955.80, reflecting a decrease of about 4.1%[27]. - Payments for goods and services increased significantly to $109,909,800.69 from $50,171,363.98, an increase of approximately 118.5%[27]. - Payments to employees rose to $27,773,229.79 from $23,837,921.36, an increase of about 16.5%[27]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,433,541,057.65, a decrease of 0.91% from CNY 1,402,312,065.83 at the end of the previous year[5]. - The total assets decreased slightly to ¥1,433,541,057.65 from ¥1,446,715,474.87, a decline of 0.9%[21]. - Total liabilities decreased to ¥666,647,200.24 from ¥706,898,011.15, a reduction of 5.7%[21]. - The company's equity increased to ¥766,893,857.41, up from ¥739,817,463.72, reflecting a growth of 3.7%[21]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 29,777, with the largest shareholder holding 29.93% of the shares[11]. - The company reported a total of 90,785,250 shares held by Gansu Pharmaceutical Investment Group Co., Ltd., representing 0.55% of total shares[12]. - The top ten shareholders include Gansu Xinglong Capital Management Co., Ltd. with 21,575,777 shares, accounting for 0.47% of total shares[12]. - The total number of shares held by the top ten unrestricted shareholders is 90,785,250, with no changes reported in the financing and securities lending activities[12]. - The company has not disclosed any significant changes in the shareholder relationships or actions among the top ten shareholders[12]. Research and Development - Research and development expenses increased to ¥5,999,802.11, up from ¥5,178,710.13, indicating a focus on innovation[23]. - The company acquired 70% equity of Gansu Pharmaceutical Group Technology Innovation Research Institute for RMB 85.8494 million to enhance its research capabilities and market competitiveness[16]. - The company has completed the industrial and commercial registration for the acquisition of the research institute, which is now included in the consolidated financial statements[16]. - The company aims to reduce related party transactions and enhance its independence through this acquisition[16]. Operating Costs and Expenses - The company's operating costs increased by 58.03% year-on-year, primarily due to increased sales revenue from pharmaceuticals and lower gross margins from medical devices[9]. - Total operating costs amounted to ¥247,299,967.41, up from ¥221,232,697.25, reflecting a rise of 11.8%[23]. - The company reported a significant increase in sales expenses, totaling ¥118,896,805.76, compared to ¥135,189,244.13 in the previous period, indicating a strategic shift in marketing efforts[23]. - The company reported a 75.00% decrease in financial expenses compared to the previous year, attributed to loan repayments and increased interest income[9]. Cash and Cash Equivalents - As of March 31, 2025, the company's cash and cash equivalents decreased to RMB 274,849,268.71 from RMB 310,022,521.29 at the beginning of the period, reflecting a decline of approximately 11.4%[19]. - The ending cash and cash equivalents balance decreased to $274,849,268.71 from $340,758,258.95, a decline of approximately 19.3%[28].

陇神戎发（300534）公告，2025年第一季度营业收入2.89亿元，同比增长13.52%。净利润2421万元，同 比增长9.18%。 ...